[Triple immunosuppressive therapy in the treatment of severe ulcerative colitis]. 2004

B Castro, and J Crespo, and C García-Suárez, and E Fábrega, and F Casafont, and F Pons-Romero
Servicio de Aparato Digestivo, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, España.

BACKGROUND Severe episodes of steroid-refractory ulcerative colitis (UC) were considered an indication for surgery until the introduction of new immunosuppressive agents such as cyclosporine. OBJECTIVE 1) To confirm the efficacy of intravenous cyclosporine in inducing remission in severe episodes of steroid-refractory UC; 2) To analyze the efficacy of triple immunosuppressive therapy with cyclosporine, azathioprine and prednisone in the maintenance of remission induced by intravenous cyclosporine. METHODS Fourteen patients diagnosed with a severe episode of steroid-refractory UC were treated with intravenous cyclosporine at a dose of 4 mg/kg/day. In all patients, after response was induced, this regimen was substituted by oral cyclosporine plus azathioprine at a dose of 2-2.5 mg/kg/day and decreasing doses of corticoids. Neoral cyclosporine was progressively reduced until discontinuation within 3 months, coinciding with a simultaneous decrease of oral steroids. RESULTS All patients showed response to intravenous cyclosporine with a significant reduction in the Truelove index calculated before and after treatment. After remission was induced, all patients followed triple immunosuppressive therapy for 3 months. In the follow-up for a mean of 24 months (range: 14-34) only two patients required admission for a new episode of UC and colectomy was finally indicated in only one. None of the 14 patients treated with cyclosporine showed severe adverse effects attributable to the drug. CONCLUSIONS Intravenous cyclosporine is a safe and effective alternative in the treatment of severe episodes of steroid-refractory UC. Early initiation of oral administration associated with azathioprine is useful in maintaining response, reducing subsequent relapses and the need for colectomy during the follow-up of these patients.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003093 Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN. Colitis Gravis,Idiopathic Proctocolitis,Inflammatory Bowel Disease, Ulcerative Colitis Type,Ulcerative Colitis
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity

Related Publications

B Castro, and J Crespo, and C García-Suárez, and E Fábrega, and F Casafont, and F Pons-Romero
May 1969, Proceedings of the Royal Society of Medicine,
B Castro, and J Crespo, and C García-Suárez, and E Fábrega, and F Casafont, and F Pons-Romero
June 1972, Orvosi hetilap,
B Castro, and J Crespo, and C García-Suárez, and E Fábrega, and F Casafont, and F Pons-Romero
January 1971, Medicinski glasnik,
B Castro, and J Crespo, and C García-Suárez, and E Fábrega, and F Casafont, and F Pons-Romero
November 1999, Nihon rinsho. Japanese journal of clinical medicine,
B Castro, and J Crespo, and C García-Suárez, and E Fábrega, and F Casafont, and F Pons-Romero
June 1972, Monatsschrift fur Kinderheilkunde,
B Castro, and J Crespo, and C García-Suárez, and E Fábrega, and F Casafont, and F Pons-Romero
January 1978, Progress in pediatric surgery,
B Castro, and J Crespo, and C García-Suárez, and E Fábrega, and F Casafont, and F Pons-Romero
December 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,
B Castro, and J Crespo, and C García-Suárez, and E Fábrega, and F Casafont, and F Pons-Romero
August 1972, The Surgical clinics of North America,
B Castro, and J Crespo, and C García-Suárez, and E Fábrega, and F Casafont, and F Pons-Romero
April 2023, Clinical journal of gastroenterology,
B Castro, and J Crespo, and C García-Suárez, and E Fábrega, and F Casafont, and F Pons-Romero
December 2012, Expert opinion on emerging drugs,
Copied contents to your clipboard!